APi Group (APG) Q2 Revenue Jumps 15%

09:10am, Friday, 01'st Aug 2025
APi Group (APG) Q2 Revenue Jumps 15%
APi Group Corporation (NYSE:APG ) Q2 2025 Earnings Conference Call July 31, 2025 8:30 AM ET Company Participants Adam Fee - Vice President of Investor Relations Glenn David Jackola - Executive VP & CF
The Zacks Business Services industry is poised to prosper with rising demand and growing technology adoption. APG, ARMK and MITFY are three stocks that appear well-poised to ride this demand strength.
The headline numbers for APi (APG) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and

APi (APG) Beats Q2 Earnings and Revenue Estimates

09:45am, Thursday, 31'st Jul 2025
APi (APG) came out with quarterly earnings of $0.39 per share, beating the Zacks Consensus Estimate of $0.37 per share. This compares to earnings of $0.33 per share a year ago.
NEW BRIGHTON, Minn.--(BUSINESS WIRE)--APi Group Corporation (NYSE: APG) (“APi” or the “Company”) today reported its financial results for the three and six months ended June 30, 2025. Russ Bec
Here is how APi (APG) and HNI (HNI) have performed compared to their sector so far this year.
APi (APG) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Starting July 21, 2025, APi Group Corp APG enters the 9th Phase of its 18-Phase Adhishthana Cycle on the weekly chart. At first glance, the structure appears healthy.
Does APi (APG) have what it takes to be a top stock pick for momentum investors? Let's find out.
NEW BRIGHTON, Minn.--(BUSINESS WIRE)--APi Group Corporation (NYSE: APG) (“APi” or the “Company”) announced today that it intends to release its financial results for the three and six months e
APi (APG) is well positioned to outperform the market, as it exhibits above-average growth in financials.
APi (APG) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Apogee Therapeutics, Inc.'s APG777 shows best-in-class week-16 efficacy and quarterly/semi-annual dosing potential. In my view, this could give this drug candidate a great competitive profile. In fact
APEX Part A met all primary and key secondary endpoints and exceeded trial objectives, including 7 1.0% decrease  from baseline in EASI at Week 16
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE